TEAD Inhibitors

Transcriptional Enhanced Associate Domain (TEAD) proteins (TEAD1-4) are a family of transcription factors that serve as the primary nuclear effectors of the Hippo signaling pathway. The Hippo pathway is a highly conserved signaling cascade that plays a fundamental role in regulating organ size, cell proliferation, apoptosis, and stem cell self-renewal. When the Hippo pathway is active, the transcriptional co-activators YAP (Yes-associated protein) and TAZ (transcriptional co-activator with PDZ-binding motif) are phosphorylated by the LATS1/2 kinases, leading to their cytoplasmic retention or degradation. Conversely, when the Hippo pathway is inactive (e.g., due to low cell density, mechanical cues, or oncogenic mutations), unphosphorylated YAP/TAZ translocate to the nucleus, where they bind to TEAD proteins. TEAD proteins directly bind to specific DNA sequences in the promoters of target genes, but they require the interaction with YAP/TAZ to activate transcription. This complex then drives the expression of genes involved in cell growth, survival, proliferation, and epithelial-mesenchymal transition (EMT). Dysregulation and hyperactivation of the Hippo-YAP/TAZ-TEAD pathway are frequently observed in a wide range of human cancers, making TEAD proteins highly attractive drug targets. Overactivation of YAP/TAZ-TEAD signaling contributes to tumor initiation, progression, metastasis, and drug resistance in various solid tumors, including mesothelioma, lung cancer (especially non-small cell lung cancer), liver cancer (hepatocellular carcinoma), breast cancer, ovarian cancer, and head and neck squamous cell carcinoma. In these cancers, the sustained activation of TEAD-mediated transcription promotes uncontrolled cell proliferation, inhibits apoptosis, and enhances invasive capabilities, driving aggressive disease phenotypes.

Therefore, inhibiting the YAP/TAZ-TEAD interaction or TEAD activity represents a promising strategy to suppress tumor growth and overcome resistance to conventional therapies. Research into TEAD inhibitors is predominantly in the preclinical stage, with several compounds having advanced into early clinical trials. Various strategies are being pursued to inhibit TEAD activity. One prominent approach involves targeting the palmitoylation of TEAD proteins, a post-translational modification crucial for their interaction with YAP/TAZ. VT104, a P-TEAD inhibitor that interferes with TEAD palmitoylation, has entered clinical trials for mesothelioma and other solid tumors, showing promising early results. Another major strategy focuses on developing small molecules that directly disrupt the protein-protein interaction interface between YAP/TAZ and TEAD. While early compounds like Verteporfin showed some activity, they often lacked specificity. More selective and potent YAP/TAZ-TEAD interaction inhibitors are now being developed by pharmaceutical companies, with several proprietary compounds in preclinical optimization. Additionally, some efforts explore inhibitors that interfere with TEAD's DNA-binding capabilities, although this approach is less common.

TEAD inhibitors are primarily classified by their mechanism of action: P-TEAD inhibitors (targeting palmitoylation), YAP/TAZ-TEAD protein-protein interaction (PPI) inhibitors, and less commonly, TEAD DNA-binding inhibitors. They are also categorized by their chemical structure (e.g., small molecules, peptides). The goal is to develop highly selective inhibitors that specifically target the TEAD-YAP/TAZ complex without affecting other crucial transcription factors or signaling pathways. The development of pan-TEAD inhibitors versus isoform-specific inhibitors (e.g., TEAD1 vs. TEAD4) is also an area of consideration, given potential functional differences among the TEAD family members. Key challenges in developing TEAD inhibitors include achieving high selectivity and potency, ensuring favorable pharmacokinetic properties, and addressing potential toxicity concerns given the broad physiological roles of the Hippo pathway. The complexity of the Hippo pathway and potential compensatory mechanisms also pose hurdles. Research tools include reporter assays for TEAD transcriptional activity, co-immunoprecipitation assays to study YAP/TAZ-TEAD interactions, and genetic models (e.g., conditional knockout mice) to validate target engagement and efficacy. Combination therapy strategies are highly promising, where TEAD inhibitors could be combined with standard chemotherapies, targeted therapies (e.g., EGFR inhibitors in lung cancer), or immunotherapies to enhance anti-tumor responses, particularly in cancers where YAP/TAZ activation confers resistance.

Patient stratification based on Hippo pathway activation status (e.g., high nuclear YAP/TAZ) will be crucial for identifying responders and guiding clinical development.